MoonLake Immunotherapeutics Advances Sonelokimab Through Phase 3 Trials for Multiple Inflammatory Conditions
核心洞察
MoonLake Immunotherapeutics is advancing Sonelokimab, a novel Nanobody® targeting IL-17A/A, A/F, and F/F dimers, through multiple Phase 3 trials for immunologic diseases.
The Phase 3 VELA trials for hidradenitis suppurativa (搜索) launched in May 2025 with results expected in mid-2025, while the Phase 3 IZAR program for psoriatic arthritis (搜索) begins in Q4 2024.
The company is expanding into new indications including palmoplantar pustulosis (搜索) and axial spondyloarthritis (搜索), with Q2 2025 results scheduled for August 7.
MoonLake Immunotherapeutics (NASDAQ:MLTX), a Switzerland-based clinical-stage biopharmaceutical company, is accelerating its clinical development program for Sonelokimab, an investigational Nanobody® designed to treat inflammatory diseases (搜索). The company is advancing multiple Phase 3 trials across several immunologic conditions, marking a significant milestone in its development pipeline.
Novel Mechanism Targets Multiple IL-17 Dimers
Sonelokimab, also known as M1095 or ALX-0761, represents a next-generation approach to treating inflammatory diseases (搜索) by independently inhibiting the naturally occurring IL-17 A/A, A/F, and F/F dimers that drive inflammation. This novel mechanism distinguishes the therapy from existing treatments in the inflammatory disease space.
Phase 3 Programs Show Clinical Momentum
The company has launched the Phase 3 VELA trials for hidradenitis suppurativa (搜索) in May 2025, with results expected to arrive in mid-2025. Building on positive Phase 2 results in psoriatic arthritis (搜索), MoonLake is initiating the Phase 3 IZAR program in Q4 2024, with the primary endpoint readout at week 16 expected in the first half of 2026.
Expanding Indication Portfolio
Beyond its core programs, MoonLake is pursuing additional indications including palmoplantar pustulosis (搜索) and axial spondyloarthritis (搜索), with multiple trials currently underway. The company has scheduled Q2 2025 results for August 7, providing investors with near-term catalysts to assess the therapy's broader potential.
Investment Landscape
The clinical advancement comes amid mixed investor sentiment, with the company having experienced a Phase 3 trial miss that has impacted valuation. Despite this setback, institutional confidence remains modest, with 38 hedge funds currently holding stakes in the company. The accelerated clinical timeline and expanded indication portfolio represent potential value drivers as the company works to demonstrate Sonelokimab's therapeutic potential across multiple inflammatory conditions.